TuHURA Biosciences Amends Prior 8-K to Correct Pro Forma Financial Statements for Kineta Merger
HURA has more than doubled off its 52-week low of $0.41 on light trading volume (0.3× avg).
Summary
TuHURA Biosciences filed an amended 8-K to correct errors in the pro forma financial statements for the Kineta acquisition, replacing the entire Exhibit 99.1.
Key Events · Corporate Governance and Compliance · HURA
-
Corrects Pro Forma Financials
The company filed an 8-K/A to amend its prior 8-K from April 8, 2026, specifically to correct errors in the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2025, related to the Kineta acquisition.
-
Replaces Exhibit 99.1
The amendment replaces the entire Exhibit 99.1, which contains the revised pro forma financial statements, ensuring a more accurate representation of the combined entity's simulated financial performance post-merger.
-
Pro Forma Net Loss Reported
The corrected pro forma statements show a net loss attributable to common stockholders of $(34,571,619) and weighted-average shares outstanding of 52,737,089 for the year ended December 31, 2025.
Analysis · HURA · Life Sciences
This amendment addresses errors in the previously filed pro forma financial statements related to the Kineta acquisition. For a company operating under a going concern warning and actively raising capital, accurate financial reporting, even for pro forma figures, is crucial for investor confidence and assessing the post-merger financial outlook. The correction of these errors provides a more reliable picture of the combined entity's simulated financial performance.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HURA was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $142.4M. The 52-week trading range was $0.41 to $4.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.